The present study evaluated the predictive value of blood-borne inflammation markers including CRP, NLR, PLR, and SII in relation to treatment response and survival in patients with HNSCC receiving anti-PD-1 immunotherapy. This evidence concerns the gene CRP and head and neck squamous cell carcinoma.